Christie Edward M III 4
4 · Encompass Health Corp · Filed Apr 16, 2026
Research Summary
AI-generated summary of this filing
Encompass Health Director Christie Edward M III Acquires 270 Shares
What Happened
Christie Edward M III, a non‑employee director of Encompass Health Corp (EHC), had two acquisition transactions reported. On April 15, 2026 he was credited with 9 restricted stock units (RSUs) related to a $0.19 per‑share dividend (reported at $0.00 cash). On April 16, 2026 he acquired 261 shares in the market under the company’s Directors Deferred Stock Investment Plan at a weighted average price of $106.17 per share for a total of $27,710. Both filings are reported as acquisitions (code A).
Key Details
- Transaction dates: April 15, 2026 (9 RSUs credited); April 16, 2026 (261 shares purchased).
- Prices/values: 9 RSUs reported at $0.00 (dividend‑credited award); 261 shares at a weighted avg $106.17; total purchase ≈ $27,710. Purchases executed in multiple trades at $106.11–$106.17.
- Shares owned after transaction: Not stated in the provided filing excerpt.
- Footnotes of note:
- F1: The 9 RSUs were credited as additional RSUs tied to the $0.19 per‑share dividend; closing price on dividend payment date was $105.24.
- F2: The 261 shares were bought by the plan using fees deferred by the director and include reinvested dividends.
- F3: The $106.17 price is a weighted average (range $106.11–$106.17); full per‑lot price breakdown available on request.
- Timeliness: Filing covers activity through April 15, 2026 and was filed April 16, 2026 (appears timely).
Context
The April 15 RSU credit reflects dividend reinvestment into additional RSUs under existing awards; the April 16 acquisition was a purchase funded by deferred director fees under the Directors Deferred Stock Investment Plan. These are routine non‑employee director compensation and deferral transactions rather than open‑market discretionary buys by an executive.
Insider Transaction Report
- Award
Encompass Health Common Stock
[F1]2026-04-15+9→ 7,191 total - Award
Encompass Health Common Stock
[F2][F3]2026-04-16$106.17/sh+261$27,710→ 7,452 total
Footnotes (3)
- [F1]Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $105.24. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.
- [F2]The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the director's fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on April 15, 2026.
- [F3]This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $106.11 to $106.17, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.